“This business is going to be a fast-growing business for this company throughout our long-range plan period and is really based on a new product story very much like the Human Health business.”

In context

“. Enlicitide, our oral PCSK9, we continue to think is a huge opportunity. And we'll continue to focus on what we have in MK-6024, which is our MASH product. We're going to see, I think, data later this year. We continue to feel very good about that. So our overall suite of the cardiometabolic space, we feel very good about. That's the $15 billion. Ophthalmology, I think, is underappreciated with a multibillion-dollar opportunity. We just recently went through our HIV portfolio with approximately $5 billion of opportunity. And we feel very good about that and the data we have and where our portfolio is going to go is very important. Immunology is another $5 billion, which is important to focus on. Animal Health, you look at the quarter of the growth we showed in Animal Health this quarter. This business is going to be a fast-growing business for this company throughout our long-range plan period and is really based on a new product story very much like the Human Health business. We actually just got approval in Europe for NUMELVI, our JAK inhibitor for dermatitis. We just got approval for our injectable once annual in the United States. Those are the first of multiple new product offerings coming in that business that is going to allow us to more than double it by the time we get out to the mid-2030s. And then all of this excludes what else we're going to do in business development. The fact that we just did Ohtuvayre, which added another multibillion-dollar opportunity that wasn't in that $50 billion when we said it, is further block -- building block being added as well. And then we still have a lot to do on business development. We've been very clear. We're not stopping. And we have an early- stage pipeline, which as we move into '26 and especially into 27, yo”